Ganaxolone

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Ganaxolone

Examples of brand names: Ztalmy [EU/USA]

ATC code: N03AX27

Main use (for orientation): CDKL5-associated epilepsy

Documented research summary

CBD plus ganaxolone showed synergistic or additive anticonvulsant effects in adult mice. No clinical combination evidence. Official pharmacokinetics/pharmacodynamics support possible questions about sedation and metabolism, not a quantified clinical CBD drug–drug interaction.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: B0341

Type of result: Preclinical evidence

Observation: 6 Hz mouse model: isobolographic synergy (combination index 0.313); kindling model: synergistic/additive protection.

Mechanism: Combined anticonvulsant effect

Study type: Mouse models

Context studied: CBD ED50 53 mg/kg i.p. in the 6 Hz model, combinations 1:1/1:3/3:1; not a clinical dosing proposal.

Clinical interpretation: Do not transfer study conditions to individual use.

Limitations and uncertainties: Only abstracts available; no human drug–drug interaction/pharmacokinetics proven.

Original sources for this finding: Isobolographic analysis of adjunct antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy. [C_PR_36493860]; Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures. [C_PR_36216124]

References and access status

[C_LABEL_D0064] ZTALMY (GANAXOLONE) SUSPENSION [IMMEDICA PHARMA US INC]

Original source / bibliographic reference

Authors: IMMEDICA PHARMA US INC

Year: 2026

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[C_PR_36493860] Isobolographic analysis of adjunct antiseizure activity of the FDA-approved cannabidiol with neurosteroids and benzodiazepines in adult refractory focal onset epilepsy.

Original source / bibliographic reference

Authors: Golub V, Ramakrishnan S, Reddy DS.

Year: 2023

Source type: Primary source, abstract read

DOI: 10.1016/j.expneurol.2022.114294

PMID: 36493860

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_36216124] Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures.

Original source / bibliographic reference

Authors: Reddy DS, Mbilinyi RH, Ramakrishnan S.

Year: 2023

Source type: Primary source, abstract read

DOI: 10.1016/j.expneurol.2022.114240

PMID: 36216124

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility